封亮, 柯仲成, 汪刚, 林传燕, 石心红, 贾晓斌. 赤芍萜苷组分抗缺血缺氧损伤的代表性成分的发现与验证J. 药学学报, 2018,53(12): 1954-1962. doi: 10.16438/j.0513-4870.2018-0437
引用本文: 封亮, 柯仲成, 汪刚, 林传燕, 石心红, 贾晓斌. 赤芍萜苷组分抗缺血缺氧损伤的代表性成分的发现与验证J. 药学学报, 2018,53(12): 1954-1962. doi: 10.16438/j.0513-4870.2018-0437
FENG Liang, KE Zhong-cheng, WANG Gang, LIN Chuan-yan, SHI Xin-hong, JIA Xiao-bin. Discovery and verification of representative ingredients of Chishao terpene glucoside components against ischemia and hypoxia injuryJ. Acta Pharmaceutica Sinica, 2018,53(12): 1954-1962. doi: 10.16438/j.0513-4870.2018-0437
Citation: FENG Liang, KE Zhong-cheng, WANG Gang, LIN Chuan-yan, SHI Xin-hong, JIA Xiao-bin. Discovery and verification of representative ingredients of Chishao terpene glucoside components against ischemia and hypoxia injuryJ. Acta Pharmaceutica Sinica, 2018,53(12): 1954-1962. doi: 10.16438/j.0513-4870.2018-0437

赤芍萜苷组分抗缺血缺氧损伤的代表性成分的发现与验证

Discovery and verification of representative ingredients of Chishao terpene glucoside components against ischemia and hypoxia injury

  • 摘要: 组分的发现与确证是组分制剂研究的前提。分子对接技术与药效活性评价为赤芍萜苷组分(CSTGCS)抗缺血缺氧损伤的代表性成分发现并验证提供有效方法。本研究采用UPLC-TOF/MS/MS定性分析CSTGCS的化学成分,与心肌缺血关键受体蛋白进行分子对接,并以Libdockscore筛选主要活性成分;建立H9c2细胞缺氧损伤模型,以肌酸激酶(CK)、乳酸脱氢酶(LDH)、超氧化物歧化酶(SOD)、丙二醛(MDA)为评价指标,辨识能代表CSTGCS防治心肌缺血的成分组合;进一步以细胞凋亡指数、凋亡蛋白和线粒体相关mRNA表达,验证其对缺氧细胞凋亡的抑制作用,最终确定CSTGCS的代表性成分。结果显示,芍药苷、芍药内酯苷、苯甲酰芍药苷和氧化芍药苷可与4TWT、3O4O、4KZN和1M9J等靶蛋白在空间、能量上匹配且含量较高,为CSTGCS的主要活性成分;在调节CK、LDH、SOD、MDA和维持线粒体功能、抑制细胞凋亡方面,芍药苷+芍药内酯苷+苯甲酰芍药苷组合与CSTGCS作用无统计学差异,确定为CSTGCS抗缺血缺氧损伤的代表性成分,为组分整体性质及制剂研究提供依据。

     

    Abstract: The discovery and verification of components are prerequisites for developing of component preparations. The molecular docking technique and pharmacodynamic activity evaluation provide effective methods for the discovery and verification of the representative components of Chishao terpene glucoside components (CSTGCS) against ischemia and hypoxia injury. The chemical constituents of CSTGCS were analyzed qualitatively by UPLC-TOF/MS/MS. Main chemical constituents were docked with key receptor proteins of myocardial ischemia to preliminarily screen anti-ischemia active ingredients, and screening for main active ingredients with Libdockscore. Then a H9c2 cell hypoxia injury model was established, and creatine kinase (CK), lactate dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA) were determined to screen the representative combinations in CSTGCS. In addition, apoptosis index, apoptotic protein expression and mitochondria-associated mRNA levels were determined to verify the inhibition of the representative components (RCS) on the apoptosis of hypoxic cells. Eventually, the representative components of CSTGCS were determined. The results showed that paeoniflorin, albiflorin, benzoyl paeoniflorin and oxypaeoniflorin were considered to be the main active components because of their high matching with target proteins (4TWT, 3O4O, 4KZN, 1M9J) in space and energy. There was no statistical difference in regulating CK, LDH, SOD, MDA levels and maintaining mitochondrial function as well as inhibiting cell apoptosis between CSTGCS group and RCS group (paeoniflorin + albiflorin + benzoyl paeoniflorin combination). Therefore, paeoniflorin, albiflorin and benzoyl paeoniflorin were selected as the most representative ingredients of CSTGCS against ischemia and hypoxia injury, providing a basis for the overall properties of the components and formulation of CSTGCS.

     

/

返回文章
返回